ArticleMolecular and clinical oncology2019
An updated review of mucosal melanoma: Survival meta-analysis.
Article in Molecular and clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 37 citations in OpenAlex.
- Mucosal melanoma in 1481 patients in the Netherlands. An overview of metastatic patterns, main driver mutations and the efficacy of therapeutic strategies.BJC reports · 2026Article
- Article
- Tissue-specific inflammation induces cell state plasticity with oncogenic addiction in mucosal melanoma.Science advances · 2026Article
- Testing patterns, patient and tumour characteristics and survival by NRAS and KIT genotype in melanoma.Clinical and experimental dermatology · 2026Article
- Article
- Prognostic Value of Systemic Immune-Inflammation Index in Mucosal Malignant Melanoma.Journal of clinical medicine · 2026Article
- Line-Field Confocal Optical Coherence Tomography for the Evaluation of Pigmented Skin Lesions of the Genital Area.Diagnostics (Basel, Switzerland) · 2025Article
- Factors Affecting Recurrence and Survival for Patients with High-Risk Stage II Melanoma.Annals of surgical oncology · 2024Article
- Neoadjuvant ipilimumab plus nivolumab therapy as a potential organ preservation strategy in mucosal melanoma: case report.Frontiers in oncology · 2024Article
- Review
- Dramatic response to radiation of a sinus melanoma: A case report.Clinical case reports · 2023Article
- Trends in Incidence and Survival of 1496 Patients with Mucosal Melanoma in The Netherlands (1990-2019).Cancers · 2023Article
- A nomogram for predicting overall survival of patients with sinonasal melanoma: A population-based study.Laryngoscope investigative otolaryngology · 2022Article
- Epidemiology and Molecular Profile of Mucosal Melanoma: A Population-Based Study in Southern Europe.Cancers · 2022Article
- Prognostic Roles ofCells · 2021Article
- Mucosal Melanoma: Pathological Evolution, Pathway Dependency and Targeted Therapy.Frontiers in oncology · 2021Review
- RAGE Signaling in Melanoma Tumors.International journal of molecular sciences · 2020Review
- Epidemiology and survival outcomes of primary gastrointestinal melanoma: a SEER-based population study.International journal of clinical oncology · 2020Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucosal melanoma (MM) is a highly lethal variant of melanoma that carries a poor prognosis. Extremely low incidence and survival rates have led to few clinical trials, and a lack of protocols and guidelines. The present study performed a survival meta-analysis for the quantitative synthesis of available evidence to search for key patterns that would help clinicians tailor optimal therapeutic strategies in MM. PubMed, EMBASE, Cochrane, MEDLINE, Google Scholar and other databases were searched. Hazard ratios, in disease-specific and overall survival, were calculated for each of the survival-determining variables. MM was 2.25 times more lethal than cutaneous melanoma (CM). The most significant threats to survival were advanced Tumor-Node-Metastasis stage, sino-nasal location, and old age. Chemotherapy was the most effective form of adjuvant therapy. Disease-specific survival, the primary measure of the effect sizes, can fluctuate depending on the accuracy of the reported cause of mortality. In conclusion, MM is a peculiar type of melanoma, with clinical and molecular profile vastly different from the much-familiar CM. In the wake of the era of precision oncology, further studies on driver mutations and oncogenic pathways would likely lead to improved patient survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.